AU2009267113A1 - Anti-GD2 antibodies and methods and uses related thereto - Google Patents

Anti-GD2 antibodies and methods and uses related thereto Download PDF

Info

Publication number
AU2009267113A1
AU2009267113A1 AU2009267113A AU2009267113A AU2009267113A1 AU 2009267113 A1 AU2009267113 A1 AU 2009267113A1 AU 2009267113 A AU2009267113 A AU 2009267113A AU 2009267113 A AU2009267113 A AU 2009267113A AU 2009267113 A1 AU2009267113 A1 AU 2009267113A1
Authority
AU
Australia
Prior art keywords
antigen
antibody
seq
binding fragment
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009267113A
Other languages
English (en)
Inventor
Wolfgang Ebel
Luigi Grasso
Nicholas C. Nicolaides
Eric Routhier
Philip M. Sass
Jun Yao
Yuhong Zhou
Xun Zuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphotek Inc
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of AU2009267113A1 publication Critical patent/AU2009267113A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2009267113A 2008-06-30 2009-06-30 Anti-GD2 antibodies and methods and uses related thereto Abandoned AU2009267113A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7704108P 2008-06-30 2008-06-30
US61/077,041 2008-06-30
US9703408P 2008-09-15 2008-09-15
US61/097,034 2008-09-15
PCT/US2009/049139 WO2010002822A1 (en) 2008-06-30 2009-06-30 Anti-gd2 antibodies and methods and uses related thereto

Publications (1)

Publication Number Publication Date
AU2009267113A1 true AU2009267113A1 (en) 2010-01-07

Family

ID=41139062

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009267113A Abandoned AU2009267113A1 (en) 2008-06-30 2009-06-30 Anti-GD2 antibodies and methods and uses related thereto

Country Status (11)

Country Link
US (3) US8278065B2 (https=)
EP (1) EP2310416A1 (https=)
JP (1) JP5654986B2 (https=)
KR (1) KR20110025859A (https=)
CN (1) CN102164962B (https=)
AU (1) AU2009267113A1 (https=)
CA (1) CA2729499A1 (https=)
IL (1) IL210147A0 (https=)
MX (1) MX2010014364A (https=)
TW (1) TWI466684B (https=)
WO (1) WO2010002822A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102164962B (zh) 2008-06-30 2014-05-28 诺福泰克公司 抗gd2抗体和方法及其相关应用
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
EP2925783B1 (en) 2012-11-30 2020-07-29 Katinger GmbH Recombinant human igm-antibody effective against cancer cells
SG11201600853UA (en) 2013-08-05 2016-03-30 Twist Bioscience Corp De novo synthesized gene libraries
US10447673B2 (en) * 2013-08-05 2019-10-15 Sony Corporation Information processing apparatus, information processing method, and computer program
ES2768649T3 (es) 2013-11-21 2020-06-23 Apeiron Biologics Ag Preparaciones para tratar un cáncer positivo para GD2
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
CA2971151C (en) * 2014-01-09 2020-10-27 Kentucky Bioprocessing, Inc. Method of purifying monoclonal antibodies
ES2866935T3 (es) 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10294306B2 (en) * 2015-05-28 2019-05-21 Bio-Rad Laboratories, Inc. Affinity ligands and methods relating thereto
EP3350314A4 (en) 2015-09-18 2019-02-06 Twist Bioscience Corporation OLIGONUCLEIC ACID VARIANT LIBRARIES VARIANT AND SYNTHESIS THEREOF
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
PL3368571T3 (pl) 2015-10-30 2023-05-02 The Regents Of The University Of California Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP4556433A3 (en) 2017-02-22 2025-08-06 Twist Bioscience Corporation Nucleic acid based data storage
WO2018231872A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US11407837B2 (en) 2017-09-11 2022-08-09 Twist Bioscience Corporation GPCR binding proteins and synthesis thereof
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
WO2020139871A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
JP2022522668A (ja) 2019-02-26 2022-04-20 ツイスト バイオサイエンス コーポレーション 抗体を最適化するための変異体核酸ライブラリ
CN114096240A (zh) 2019-05-17 2022-02-25 癌症预防制药股份有限公司 用于治疗家族性腺瘤性息肉病的方法
US12410238B2 (en) 2019-06-19 2025-09-09 Icahn School Of Medicine At Mount Sinai Monoclonal antibodies against JC virus
US11332738B2 (en) 2019-06-21 2022-05-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
EP4008347B1 (en) * 2019-08-01 2025-04-30 Mie University GD2-BINDING MOLECULE
EP4034566A4 (en) 2019-09-23 2024-01-24 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CRTH2
JP2022548783A (ja) 2019-09-23 2022-11-21 ツイスト バイオサイエンス コーポレーション 単一ドメイン抗体のバリアント核酸ライブラリー
BR112022011235A2 (pt) 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
CN114685658B (zh) * 2020-12-30 2024-12-17 百力司康生物医药(杭州)有限公司 Ox40的靶向抗体及其制备方法和应用
KR20230147617A (ko) 2021-01-21 2023-10-23 트위스트 바이오사이언스 코포레이션 아데노신 수용체에 관한 방법 및 조성물
TW202302648A (zh) * 2021-03-12 2023-01-16 美商健生生物科技公司 Cd79b抗體於自體免疫治療應用之用途
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5419904A (en) * 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
WO1993010221A1 (en) 1991-11-13 1993-05-27 The Regents Of The University Of California Chimeric murine/human anti-idiotype monoclonal antibodies
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
AU725329B2 (en) * 1996-09-02 2000-10-12 Ko Okumura Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
DE602004030451D1 (de) * 2003-07-15 2011-01-20 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm-produktion
FR2906808B1 (fr) * 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
CN102164962B (zh) 2008-06-30 2014-05-28 诺福泰克公司 抗gd2抗体和方法及其相关应用

Also Published As

Publication number Publication date
TW201004645A (en) 2010-02-01
TWI466684B (zh) 2015-01-01
JP2011526785A (ja) 2011-10-20
IL210147A0 (en) 2011-03-31
JP5654986B2 (ja) 2015-01-14
EP2310416A1 (en) 2011-04-20
CN102164962A (zh) 2011-08-24
US20100008851A1 (en) 2010-01-14
US20120328524A1 (en) 2012-12-27
US20130287691A1 (en) 2013-10-31
MX2010014364A (es) 2011-08-12
KR20110025859A (ko) 2011-03-11
US8507657B2 (en) 2013-08-13
US8278065B2 (en) 2012-10-02
CN102164962B (zh) 2014-05-28
US8956832B2 (en) 2015-02-17
WO2010002822A1 (en) 2010-01-07
CA2729499A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
US8956832B2 (en) Cells expressing anti-GD2 antibodies and methods related thereto
US10407506B2 (en) Anti-MCAM antibodies and associated methods of use
US8530414B2 (en) Antibodies to PCSK9 and uses thereof
JP6898925B2 (ja) Ａｓｃｔ２特異的結合分子及びその使用
US10654920B2 (en) Anti-laminin4 antibodies specific for LG4-5
JP2020503258A (ja) Ａｓｃｔ２特異的結合分子及びその使用
PT2209806E (pt) Anticorpos anti-hepcidina e as suas utilizações
US20170158755A1 (en) Anti-laminin4 antibodies specific for lg1-3
US20250277026A1 (en) Antibodies against claudin-6 and uses thereof
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
WO2018022479A1 (en) Anti-hspa5 (grp78) antibodies and uses thereof
US20170335004A1 (en) Fn14-binding proteins and uses thereof
TW202421657A (zh) 抗體或其片段、抗癌劑及抗癌用藥物組成物
TW202540203A (zh) 結合pdgf-b與pdgf-d的抗原結合分子及使用方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application